Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Ravi SavarirayanLouise ToftsMelita IrvingWilliam R WilcoxCarlos A BacinoJulie Hoover-FongRosendo Ullot FontPaul HarmatzFrank RutschMichael B BoberLynda E PolgreenIgnacio GinebredaKlaus MohnikeJoel CharrowDaniel HoernschemeyerKeiichi OzonoYasemin AlanayPaul ArundelYumiko KotaniNatsuo YasuiKlane K WhiteHoward M SaalAntonio Leiva-GeaFelipe Luna-GonzálezHiroshi MochizukiDonald BaselDania M PorcoKala JayaramElena FishelevaAlice Huntsman-LabedJonathan R S DayPublished in: Genetics in medicine : official journal of the American College of Medical Genetics (2021)
Vosoritide treatment has safe and persistent growth-promoting effects in children with achondroplasia treated daily for two years.